While GLP-1R agonists represent promising therapeutic agents due to their anti-inflammatory and regenerative properties, their potential to further impair intestinal motility and worsen constipation must be considered, particularly in IBD patients prone to slow transit. The gene discussed is GLP1R; the disease is irritable bowel syndrome.